A Study of Abicipar Pegol in Patients With Diabetic Macular Edema

Study Identifier
150998-004
CT.gov Identifier
NCT02186119
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Macular Edema
    • Study Drug
  • abicipar pegol
  • ranibizumab
    • Phase
    Phase 2
    Sex
    Female & Male
    Age
    19+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Diagnosis of diabetes mellitus (Type 1 or 2) * Decreased vision due to diabetic macular edema in at least 1 eye * Best corrected visual acuity of 20/32 to 20/320 in the study eye and 20/200 or better in the fellow eye
    Exclusion Criteria:
    * Stroke or heart attack within the past 3 months * History of vitrectomy, macular surgery, or glaucoma surgery in the study eye * Cataract or refractive surgery in the study eye within the last 3 months * Laser photocoagulation of the study eye within the last 3 months

    Protocol Summary

    This is a safety and efficacy study of abicipar pegol in patients with diabetic macular edema.

    Study Locations

    Location
    Status
    Location
    Gilbert, Arizona, United States
    Status
    Not applicable
    Location
    Abilene, Texas, United States
    Status
    Not applicable